Old West Investment Management LLC Grows Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Old West Investment Management LLC boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 11.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 380,240 shares of the biopharmaceutical company's stock after acquiring an additional 39,799 shares during the period. Amicus Therapeutics accounts for 1.5% of Old West Investment Management LLC's holdings, making the stock its 23rd biggest position. Old West Investment Management LLC owned about 0.13% of Amicus Therapeutics worth $3,582,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in FOLD. Wells Fargo & Company MN increased its stake in shares of Amicus Therapeutics by 6.0% during the fourth quarter. Wells Fargo & Company MN now owns 439,471 shares of the biopharmaceutical company's stock worth $4,140,000 after purchasing an additional 24,882 shares during the period. Massachusetts Financial Services Co. MA boosted its position in shares of Amicus Therapeutics by 3.4% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 3,267,375 shares of the biopharmaceutical company's stock valued at $30,779,000 after acquiring an additional 107,348 shares during the period. Trexquant Investment LP grew its stake in shares of Amicus Therapeutics by 101.6% in the fourth quarter. Trexquant Investment LP now owns 966,049 shares of the biopharmaceutical company's stock valued at $9,100,000 after acquiring an additional 486,827 shares in the last quarter. Headlands Technologies LLC increased its position in Amicus Therapeutics by 599.0% during the fourth quarter. Headlands Technologies LLC now owns 34,812 shares of the biopharmaceutical company's stock worth $328,000 after acquiring an additional 29,832 shares during the period. Finally, Wellington Management Group LLP raised its stake in Amicus Therapeutics by 18.8% in the 4th quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company's stock worth $268,112,000 after purchasing an additional 4,497,950 shares in the last quarter.

Amicus Therapeutics Trading Down 5.3 %

Shares of NASDAQ FOLD traded down $0.37 during midday trading on Thursday, hitting $6.53. 2,349,284 shares of the company traded hands, compared to its average volume of 2,581,297. Amicus Therapeutics, Inc. has a 12-month low of $6.20 and a 12-month high of $12.65. The firm has a market cap of $2.00 billion, a P/E ratio of -35.92, a P/E/G ratio of 1.51 and a beta of 0.79. The stock has a 50-day moving average price of $8.84 and a 200 day moving average price of $9.71. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on FOLD shares. Needham & Company LLC reissued a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Morgan Stanley reaffirmed an "equal weight" rating and issued a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. StockNews.com lowered shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, February 20th. Wells Fargo & Company reduced their target price on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, February 20th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Amicus Therapeutics has an average rating of "Moderate Buy" and an average target price of $16.75.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.